also examined preliminary estimates of effectiveness based on patient-reported outcomes. Methods Participants and Recruitment Procedures Ethics approval was obtained from the Ontario Cancer Research Ethics Board for all participating sites
Search Results
Doris Howell, Gregory R. Pond, Denise Bryant-Lukosius, Melanie Powis, Patrick T. McGowan, Tutsirai Makuwaza, Vishal Kukreti, Sara Rask, Saidah Hack, and Monika K. Krzyzanowska
Puneeth Iyengar and Robert D. Timmerman
To understand why radiation oncologists moved toward the use of SABR in treating primary NSCLCs and metastatic disease to the lungs, the poor outcomes in controlling these disease states with fractionated radiation therapy (eg, 25–37 daily treatments
Cary P. Gross, Craig S. Meyer, Sarika Ogale, Matthew Kent, and William B. Wong
in survival over the past decade. 2 Advances in personalized therapies for advanced NSCLC (aNSCLC), which allow treatment based on the genetic makeup of a tumor, have significantly contributed to the improved outcomes of patients. 2 Despite the
Krista Michelle Wong, Seshma Ramsawak, and Hasan Abuamsha
racial disparity in appendiceal cancer-specific survival exists among appendiceal cancer SEER patients. Further research is needed to address the underlying cause of these disparities in order to improve outcomes. Table: Bivariable and multivariable
Kristen Kelley, Audrey York, Benjamin Haaland, Xuechen Wang, Shiven Patel, Adriana Coletta, and Christos Vaklavas
chemotherapy may be superior. The objective of this study is to assess the relationship between dose timing and outcomes in breast cancer patients. Methods : 153 patients who had neoadjuvant chemotherapy in 2014-2020 were included. Chemotherapy administration
Eric Chen, Todd Aquino-Michaels, Sadhvi Batra, Riley Lochner, Anthony Rizzo, Ravi Kyasaram, Eleanor Harris, Tiffany Hodges, Lindsay Ferguson, and Serah Choi
Background : Even among patients with stage IV gynecologic cancers, metastases to the brain are rare and prognosis remains poor. Given the paucity of data, this study aimed to describe the outcomes of this patient population who underwent
Alejandro Garcia-Horton and Jeffrey H. Lipton
possible without widespread treatment and availability of TKIs, resulting in disease control and molecular response. Treatment-free remission (TFR) has emerged as a new goal for many patients with CML as a distinct outcome other than overall survival (OS
Kuan-Ling Kuo, David Stenehjem, Frederick Albright, Saurabh Ray, and Diana Brixner
, 31% (n=68) of patients received no treatment ( Table 3 ). From 1995 to 1998, most patients did not receive any treatment. Liver-directed therapy became more prevalent from 2007 to 2010 ( Figure 2 ). Survival Outcomes No statistically
Deepali Pandey, Quan Chen, Bin Huang, Zin Myint, and Peng Wang
Kentucky cancer Registry, diagnosed between 2004 and 2019, were included. Basic demographics and survival outcomes were compared for all stages of PC patients and between App and Non-App. We also compared the OS difference between two time periods 2004
Angela K. Green, Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, and Roisin E. O’Cearbhaill
supporting evidence that it improves outcomes. 1 , 2 Yet imaging, either in response to patient symptoms or for surveillance, is common in the management of patients with ovarian cancer in first remission among providers at academic medical centers. 3 In a
